Revelation Biosciences effects 1-for-3 reverse stock split; PRIME Phase 1b enrollment expected to complete July 2025

REVELATION BIOSCIENCES, INC.

1-for-3 reverse stock split effective July 7, 2025; post-split shares ~1,534,599.
Split intended to regain Nasdaq minimum bid price compliance; CUSIP changed to 76135L705.
PRIME Phase 1b study of Gemini in CKD patients: enrollment expected to complete July 2025; topline data anticipated shortly after.

item 3.03item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.